Hughes B, Grob J-J, Bowyer S, Day F, Ladwa R, Stein B, Muñoz-Couselo E, Basset-Seguin N, Guminski A, Mortier L, Hauschild A, Migden M, Schmults C, Yoo S-Y, Booth J, Seebach F, Lowy I, Fury M, Rischin D. Phase 2 confirmatory study of cemiplimab (350 mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s175. Available from: https://jofskin.org/33014/index.php/skin/article/view/1999